Parkman Healthcare Partners LLC Decreases Stake in United Therapeutics Corporation $UTHR

Key Points

• Parkman Healthcare Partners LLC has significantly decreased its stake in United Therapeutics Corporation by 72.7%, reducing its holdings to 10,232 shares valued at approximately $3.15 million.
• Insiders, including Director Richard Giltner and CFO James Edgemond, have sold substantial amounts of company stock recently, reflecting a combined total of shares sold worth over $39 million.
• United Therapeutics shareholders are receiving mixed signals from analysts, with Oppenheimer raising its target price to $575 while JPMorgan lowered it to $330, suggesting a current consensus rating of "Moderate Buy".

Parkman Healthcare Partners LLC decreased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 72.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,232 shares of the biotechnology company's stock after selling 27,240 shares during the quarter. Parkman Healthcare Partners LLC's holdings in United Therapeutics were worth $3,154,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Hohimer Wealth Management LLC lifted its stake in United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after purchasing an additional 37 shares during the last quarter. Applied Finance Capital Management LLC lifted its stake in United Therapeutics by 3.7% during the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 40 shares during the last quarter. Headlands Technologies LLC lifted its stake in United Therapeutics by 1.5% during the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock worth $828,000 after purchasing an additional 40 shares during the last quarter. First Financial Bankshares Inc lifted its stake in United Therapeutics by 0.3% during the first quarter. First Financial Bankshares Inc now owns 13,769 shares of the biotechnology company's stock worth $4,245,000 after purchasing an additional 42 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV lifted its stake in United Therapeutics by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,235 shares of the biotechnology company's stock worth $1,614,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other news, Director Richard Giltner sold 3,036 shares of the business's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 118,181 shares of company stock worth $39,441,679. 10.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

UTHR has been the subject of several recent analyst reports. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research note on Friday. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research note on Tuesday, July 8th. Cantor Fitzgerald reiterated an "overweight" rating on shares of United Therapeutics in a research note on Thursday, August 14th. Jefferies Financial Group boosted their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, UBS Group boosted their price objective on United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research note on Thursday. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $429.62.

United Therapeutics Trading Up 5.3%

NASDAQ:UTHR opened at $400.52 on Friday. The firm has a market cap of $18.07 billion, a P/E ratio of 15.63, a PEG ratio of 5.77 and a beta of 0.62. The stock's 50 day simple moving average is $307.69 and its 200-day simple moving average is $306.32. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the firm posted $5.85 EPS. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.